Document Detail


Optimizing the treatment of metastatic breast cancer.
MedLine Citation:
PMID:  15770536     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
There is currently no standard care for metastatic breast cancer; consequently, individual patient and tumor characteristics are among several factors considered in treatment decisions. Clinical studies continue to clarify the roles of endocrine therapy, chemotherapy, and biologic therapy, and results have been promising. For patients with hormone receptor-positive disease, several endocrine agents are currently available including selective estrogen receptor (ER) modulators (tamoxifen and toremifene), aromatase inhibitors (anastrozole, exemestane, and letrozole), as well as the selective ER down-regulator, fulvestrant. Effective first- and second-line, single-agent chemotherapeutic treatments include the taxanes, anthracyclines, vinorelbine, capecitabine, and gemcitabine. The benefits of sequential, single-agent versus combination chemotherapy are also being evaluated. Although combination chemotherapy generally results in a greater objective response, it is associated with similar survival and usually greater toxicity compared with sequential, single-agent chemotherapy. Research involving biologic therapy continues to provide encouraging results for patients with metastatic breast cancer. Chemotherapy plus trastuzumab has been shown to result in greater overall survival versus chemotherapy alone in human epidermal growth factor 2 (HER-2)-positive patients. Trastuzumab has been associated with cardiotoxicity when administered with conventional anthracyclines. Newer formulations of anthracyclines have been developed (e.g., liposomal anthracyclines) to decrease the incidence of cardiotoxicity, and these provide additional treatment options for patients with metastatic breast cancer. The potential effect of all of these endocrine, chemotherapeutic, and biologic treatments on quality of life is an important consideration. Additionally, integrating patient concerns into treatment decisions and collaborating with cross-disciplinary healthcare providers can help to manage the disease more effectively.
Authors:
Julie R Gralow
Related Documents :
18690096 - Intrathecal trastuzumab (herceptin) and methotrexate for meningeal carcinomatosis in he...
17610336 - Cost considerations in the treatment of colorectal cancer.
1688926 - Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for local...
23261596 - Specific small molecule inhibitors of skp2-mediated p27 degradation.
16138656 - Accelerometry-based feedback--can it improve movement consistency and performance in ro...
20539996 - American samoan women's health: experiences and attitudes toward breast and cervical ca...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Breast cancer research and treatment     Volume:  89 Suppl 1     ISSN:  0167-6806     ISO Abbreviation:  Breast Cancer Res. Treat.     Publication Date:  2005  
Date Detail:
Created Date:  2005-03-16     Completed Date:  2005-05-10     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8111104     Medline TA:  Breast Cancer Res Treat     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  S9-S15     Citation Subset:  IM    
Affiliation:
Department of Medicine, Division of Oncology, University of Washington School of Medicine, WA, USA. pink@u.washington.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents, Hormonal / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*,  pathology*
Clinical Trials as Topic
Down-Regulation
Female
Humans
Neoplasm Metastasis*
Prognosis
Quality of Life
Receptors, Estrogen / biosynthesis*,  drug effects,  physiology
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 0/Receptors, Estrogen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The future of breast cancer: the role of prognostic factors.
Next Document:  In vitro inhibitory effect of flavonoids on growth, infection and vacuolation of Helicobacter pylori...